Author Archives: admin


Desperate long Covid sufferers are trying every therapy, from ozone treatment to stem cell infusion – Scroll.in

People with long Covid are going online to look for support. But these valuable discussion forums, chat groups and other online peer-support networks can also spread harmful misinformation.

Online groups allow unproven therapies to be promoted, sometimes by members who believe they are sharing helpful information. Sometimes entrepreneurs are promoting their unproven therapies directly.

Health researchers admit there are few evidence-based treatments for long Covid. In the face of such uncertainty, people with debilitating symptoms can be tempted by unproven options such as blood washing, stem cell infusions and ozone treatments.

Some despairing people with long Covid say they are willing to try any therapy if theres hope it improves their health.

People with long Covid can suffer debilitating health problems that make it difficult to return to work or activities they once enjoyed. Symptoms include fatigue, brain fog, chronic pain, depression and anxiety.

They have had to fight to receive medical attention or recognition of their symptoms. Indeed, it was patient-led activism that first made the public and health professionals aware how symptoms can extend for months, even after an initially mild Covid infection.

Online discussion forums such as Reddit, as well as networks on Facebook and Twitter, have made a major difference to the long Covid community.

In the face of a lack of medical knowledge about long Covid and sometimes denial it exists, these peer networks offer emotional support and share important information about symptoms and treatments.

Reddit has a forum with tens of thousands of members discussing supplements and treatments for long Covid. This approach has been called crowdsourced medicine.

However, there are pitfalls and potential dangers of this kind of online networking and crowdsourced medicine the potential for spreading misinformation.

This issue has been a problem for a long time, particularly with other contested illnesses the medical profession has often dismissed. These include the chronic pain condition fibromyalgia and myalgic encephalomyelitis (chronic fatigue syndrome).

Weve also seen the spread of health misinformation in online patient forums and social media content about earlier infectious diseases, such as Zika virus, as well as throughout the current pandemic on topics including masks and vaccines.

Medical science is attempting to research long Covid and find treatments, but this kind of research takes time.

Meanwhile, people wanting answers and help for their symptoms are forced to turn to online sources, where the testing and review of treatments are under far less expert scrutiny.

On Reddit and other sites, the volume of content members must somehow make sense of is overwhelming.

Individuals, doctors and pharmaceutical company representatives are among those who have promoted experimental therapies that have not been thoroughly tested with clinical trials.

Some individuals or groups are exploiting peoples desperation, using long Covid support networks to attempt to profit from offering treatment plans or alternative therapies such as vitamin supplements and ozone treatment.

Some long Covid groups are are still recommended drugs such as the now scientifically discredited Covid treatment ivermectin.

Some patients have spent large sums of money on dubious therapies. Serious ethical concerns are raised by these actions, including the potential for these therapies to cause harm and worsen peoples health.

People with long Covid

People with long Covid should carefully weigh any anecdotal recommendations about treatment they come across online and think twice before sharing it.

Some have suggested a code of conduct for long Covid support groups that prohibits members from recommending treatments while allowing them to discuss their own experiences. This could help limit the spread of false information. A code of conduct could also ban the promotion of for-profit treatment programs to remove the risk of members being scammed.

However, this would require close moderation and not all sites or social media groups have such resources.

Hunting down the source of information about long Covid treatments and seeing if theres any links to published scientific evidence is another way to exercise caution.

Health workers

There are important lessons for health-care providers in understanding the needs of people with long Covid.

This includes the importance of providing a timely diagnosis and access to up-to-date valid medical information as well as acknowledging the uncertainties and distress many people feel.

Partnering with patients by acknowledging their lived expertise and together working for a solution would go a long way to help people who feel unheard and want to play an active role in improving their health.

The medical profession is beginning to recognise these issues and has also begun to identify how a better understanding of long Covid could cast light on better recognition and treatment for other contested illnesses.

Deborah Lupton is SHARP Professor, leader of the Vitalities Lab, Centre for Social Research in Health and Social Policy Centre at UNSW Sydney, and leader of the UNSW Node of the ARC Centre of Excellence for Automated Decision-Making and Society at UNSW Sydney.

This article first appeared on The Conversation.

More:
Desperate long Covid sufferers are trying every therapy, from ozone treatment to stem cell infusion - Scroll.in

Cell Therapy Technologies Market worth $8.0 billion by 2027 – Exclusive Report by MarketsandMarkets – PR Newswire

CHICAGO, Aug. 3, 2022 /PRNewswire/ --Cell Therapy Technologies Marketis projected to grow from USD 4.0 billion in 2022 to USD 8.0 billion by 2027, at a CAGR of 14.6% from 2022 to 2027, according to a new report by MarketsandMarkets.Growth in the market can be attributed to number of cell therapy clinical trials related to cancer. Furthermore, increasing incidence of communicable diseases and the growing risk of pandemics are also expected to fuel the market growth.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=213334978

Browse in-depth TOC on "Cell Therapy Technologies Market"202 Tables48 Figures218 Pages

The cell therapy equipment segment accounted for the second largest share of the product segment in the cell therapy technologies market in 2021.

The second largest share of cell therapy equipment segment can be attributed to the growing demand for these equipments. Cell therapy equipment is used in cell processing (such as cell isolation, expansion, and harvesting), cell preservation and handling, and process monitoring and quality control. The segment market is further sub-segmented into cell processing equipment, single-use equipment, and other equipment (flow cytometers, cell counters, microscopes, etc).

The stem cells segment accounted for the second largest share of the cell type segment in the cell therapy technologies market in 2021.

Rising awareness regarding the use of stem cells in the treatment of various diseases and the growing focus of players on stem cell research are driving the growth of this market segment. Rising collaboration between universities and biotechnology & biopharmaceutical companies for stem cell research and government support (availability of funding) are other important drivers.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=213334978

The Asia Pacific region is the fastest-growing region of the cell therapy technologies market in 2021.

The Asia Pacific is estimated to be the fastest-growing segment of the market. The growth of the market of the region is mostly driven by their low labor and manufacturing costs, which has drawn huge investments by biopharma giants to these countries. The increasing disposable income, growing prevalence of lifestyle and age-related chronic diseases also contribute to the high growth of the regional market.

Key players in the cell therapy technologies market include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Lonza Group (Switzerland), Sartorius AG (Germany), Terumo BCT (US), Becton, Dickinson and Company (US), Fresenius SE & Co. KGaA (Germany), Avantor, Inc. (US), Bio-Techne Corporation (US), Corning Incorporated (US), FUJIFILM Irvine Scientific (US), MaxCyte Inc. (US), Werum IT Solutions GmbH (Germany), RoosterBio Inc. (US), SIRION Biotech GmbH (Germany), TrakCel (UK), L7 Informatics, Inc. (US), Miltenyi Biotec GmbH (Germany), STEMCELL Technologies (Canada), GPI Iberia (Spain), MAK-SYSTEM (US), OrganaBio, LLC (US), IxCells Biotechnology (China), and Wilson Wolf Manufacturing Corporation (US).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=213334978

Browse Adjacent Market: Biotechnology MarketResearch Reports & Consulting

Related Reports:

Cell Culture Marketby Product (Consumables (Media, Serum, Reagent, Vessels), Equipment (Bioreactor, Centrifuge, Incubator)), Application (Vaccines, mAbs, Diagnostics, Tissue Engineering), End User (Pharma, Biotech, Hospital) - Global Forecast to 2026

About MarketsandMarkets

MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact: Mr. Aashish MehraMarketsandMarkets INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: [emailprotected] Research Insight: https://www.marketsandmarkets.com/ResearchInsight/cell-therapy-technologies-market.asp Visit Our Website: https://www.marketsandmarkets.com/ Content Source: https://www.marketsandmarkets.com/PressReleases/cell-therapy-technologies.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

SOURCE MarketsandMarkets

The rest is here:
Cell Therapy Technologies Market worth $8.0 billion by 2027 - Exclusive Report by MarketsandMarkets - PR Newswire

Blood Stem Cell Donation Know 8 Myths And Facts That You Need To Know – ABP Live

By Patrick Paul

A blood stem cell transplant is a lifesaving treatment for patients with blood cancer and other blood disorders like Thalassemia and Aplastic Anemia. In India, the burden of blood-related disorders is continuously rising with almost a lakh new cases of blood cancer every year. If patients suffering from life-threatening diseases receive timely treatment with matching potential blood stem cell donors, they can get a second chance at life.

In India, only 0.04% of the total population is registered as a potential blood stem cell donor which is significantly lower than many other countries including the US where 2.7% and Germany where 10% of the population is registered as a potential donor. Hence, the chances of finding a matching donor for Indian patients is as little as 10-15% in comparison to western countries where the chances are as high as 60-70%.

There are certain myths and misconceptions regarding the process of blood stem cell donation that often dont allow individuals to come forward and become a donor. Here are some of the most common myths:

Myth: Once you donate blood stem cells, you will lose them forever.

Fact: Only a fraction of total stem cells is extracted during the process. Also, all the cells are naturally replenished within a few weeks

Myth: Donating stem cells is a really invasive and painful process

Fact: Blood stem cells are collected through peripheral blood stem cell collection (PBSC) which is completely safe and a non-surgical procedure. The process is similar to blood platelet donation which takes approximately three to four hours to complete and the donor can leave the collection centre the same day.

Myth: Blood Donation and blood stem cell donation are the same

Fact: Unlike blood collection for transfusion, blood stem cells are collected only when there is a match between the donor and patients Human leukocyte antigen (HLA) combination (tissue type). So, you could be potentially the only match and Life Saver for a person with blood cancer in need of a transplant

Blood stem cell donors donate only blood stem cells and the process is similar to a platelet donation.

Myth: Pregnant women cant register

Fact: This is untrue, a woman can register even during her pregnancy.

Myth: Stem cell donation leaves prolonged side-effects

Fact: No, there are no major side effects post blood stem cell donation. A person may only experience minor flu-like symptoms because of the GCSF injections given to him/her before the donation, to mobilize blood stem cells in the bloodstream.

Myth: Piercing and/or tattoo is a restricting factor

Fact: Piercing or a tattoo doesnt stop you from registering yourself to be a potential donor.

Myth: My blood stem cells can be stored

Fact: Your blood stem cells will not be stored. They last for around 72 hours and are delivered to the recipient straight to the hospital by a special courier. If the recipients body accepts them, the stem cells will start making healthy blood cells.

Myth: Joining a blood stem cell registry is no use. Most patients can find a stem cell donor within their own families.

Fact: Per statistics, only 30% of blood disorder patients in need of a stem cell transplant are able to find a sibling match. About 70% of patients need an unrelated donor.

India is a data bank of potential blood stem cell donors that houses details on thousands of committed blood stem cell donors. Any patient can benefit from this registry provided an HLA match.

The author is the CEO of DKMS BMST Foundation India

Check out below Health Tools- Calculate Your Body Mass Index ( BMI )

Calculate The Age Through Age Calculator

Continued here:
Blood Stem Cell Donation Know 8 Myths And Facts That You Need To Know - ABP Live

Way Research collaborates with UPM on cure for breast cancer – The Edge Markets MY

Biotech company Way Research Academy Sdn Bhd and public university Universiti Putra Malaysia (UPM) have inked a memorandum of understanding (MoU) to undertake several projects, including jointly researching on a cure for breast cancer.

During the MoU exchange ceremony held on Wednesday (Aug 3) at Universiti Putra Malaysia Teaching Hospital (HPUPM), UPM Deputy Vice-Chancellor (Research and Innovation) Prof. Dr Nazamid Saari said that the research collaboration is to cover the fields of clinical cell therapy, immunotherapy, and food technology.

He noted that UPM's collaboration with Way Research is in line with HPUPM's UPM's medical education hospital objective of intensifying and producing high-quality research.

"Among other proposed activities is a collaboration to provide medical services to patients, which will provide mutual benefits to UPM and Way Research, as well as the patients.

"In addition, this MoU also opens up opportunities for collaboration in research and learning to improve the skills and knowledge of students and staff [of UPM], especially in the field of medicine which supports HPUPM's role as a teaching hospital," he added.

In turn, Nazamid noted that the collaboration with Way Research will elevate UPM and enable it to provide the best services to its customers, as well as cooperate and network with external organisations.

Via the MoU, the biotech company and public university have also joined hands to work on Project Raya, which entails research on a cure for breast cancer.

Way Research managing director Dr Cheng Qing Shan explained that Project Raya sets out to conduct further research into the breast cancer cure the company developed, which has been shown to effectively kill cancer cells.

"Project Raya is the research we are doing together with UPM on the cure for breast cancer. It is not a treatment, but a cure. This is done by engineering immune cells found in your body to target and destroy cancer cells, which in this case applies to breast cancer.

"Currently, Project Raya is at the stage where, in the lab, the engineered immune cells have successfully cleared the cancerous cells from the breast. Now, we are moving on to the next stage, which is an animal study," he added.

Beyond Project Raya, Cheng said the company's other projects with UPM include the construction of a good manufacturing practice (GMP) lab and cellular therapy ward to provide a safe and proper environment for patients to do immunotherapy and stem cell therapy.

"Thanks to UPM, these are just teasers of the many incredible projects we are able to explore from here.

"Ultimately, we also hope that exciting projects like these can be the start of a catalyst to attract some of our brilliant minds overseas back home to Malaysia," he added.

In lieu of corporate funding, Project Raya's continued research on its cure for breast cancer is to be publicly funded.

Thus, Way Research and UPM have enabled members of the public to voluntarily enrol in the project to support their research to further develop their chimeric antigen receptor T-cell (CAR-T) immunotherapy technology, with the goal of making it accessible to all.

"Our team of researchers have been quietly working on this project for years and recently published and made some of our findings in medical journals.

"We have completed our first phase in the lab to prove that the CAR-T immunotherapy we developed effectively attacked and cleared breast cancer cells.

"We are now ready to move towards animal study and after that into human trials. Our aim is to develop this technology and make it available and accessible to all," Way Research said.

At RM1,500, eligible individuals can opt into Project Raya to enjoy benefits of protection against the full cost of future cancer cellular therapy cost of CAR-T, immunotherapy or stem cell therapy at RM20,000 as well as complimentary blood and body check-ups with cancer marker tests.

Proceeds the project sources from the public will go towards the CAR-T immunotherapy research.

Joining Way Research and UPM on Project Raya are Klinik Central SS15 and MediCap as affiliated partners.

Klinik Central SS15 and MediCap are to also support the funding of the project via the proceeds it garners from sales of their respective medical projects and services.

For more information, members of the public or interested investors may contact Way Research by calling 018-388 6180, or visiting http://www.wayresearchacademy.com.my or the company's headquarters at No.11, Jalan SS15/8A, 47500 Subang Jaya, Selangor.

Go here to read the rest:
Way Research collaborates with UPM on cure for breast cancer - The Edge Markets MY

Stem Cell and Gene Therapy Biological Testing Market is thriving worldwide by 2029 | Top Key Players like Boehringer Ingelheim International GmbH.,…

California (United States) Stem Cell and Gene Therapy Biological Testing Marketreport focused on the comprehensive analysis of current and future prospects of the Stem Cell and Gene Therapy Biological Testing industry. It includes the primary investigations to cover historical progress, ongoing market scenarios, and future prospects defined with accurate data of the products, strategies and market shares of leading companies to help manufacturers locate the market position. The report presents a 360-degree overview of the competitive scenario of the overall market to project the size and valuation of the global Stem Cell and Gene Therapy Biological Testing Market during the forecast period.

Get the PDF Sample Copy (Including FULL TOC, Graphs, and Tables) of this report @:

Some of the Top companies Influencing this Market include:

Boehringer Ingelheim International GmbH., Elanco, Zoetis, Merck & Co. Inc, Virbac, Phibro Animal Health Corporation, Vetoquinol, Ceva, HIPRA, Dechra, CHINA ANIMAL HUSBANDRY GROUP, Kyoritsuseiyaku Corporation, Endovac Animal Health, Indian Immunologicals Pvt. Ltd., Zydus Group, UCBVET Sade e Bem Estar Animal, Neogen Corporation, American Reagent Inc, Huvepharma, Ashish Life Science, Ayurvet, Inovet Group, ECO Animal Health Ltd , Lutim Pharma Private Limited, .

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global

Global Stem Cell and Gene Therapy Biological Testing Market Segmentation:

Market Segmentation: By Type

Cell Therapy and Gene Therapy

Market Segmentation: By Application

Hospitals, Wound Care Centres, Cancer Care Centres, Ambulatory Surgical Centres and Others)

Global Stem Cell and Gene Therapy Biological Testing market Research Study Offers:

Market Overview: It includes six chapters, research scope, major manufacturers covered, market segments by type, Stem Cell and Gene Therapy Biological Testing market segments by application, study objectives, and years considered.

Market Landscape: Here, the competition in the global Stem Cell and Gene Therapy Biological Testing Market is analyzed, by price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Profiles of Manufacturers: Here, leading players of the global Stem Cell and Gene Therapy Biological Testing market are studied based on sales area, key products, gross margin, revenue, price, and production.

Market Status and Outlook by Region: In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Stem Cell and Gene Therapy Biological Testing Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User: This section of the research study shows how different end-user/application segments contribute to the global Stem Cell and Gene Therapy Biological Testing Market.

Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

Research Findings and Conclusion: This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

Get Up to 30% Discount on the first purchase of this report @:

Global Stem Cell and Gene Therapy Biological Testing market Report Scope:

The cost analysis of the Global Stem Cell and Gene Therapy Biological Testing Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy taken into consideration.

Reasons for buying this report:

Table of Contents

Global Stem Cell and Gene Therapy Biological Testing Market Research Report 2022 2029

Chapter 1 Stem Cell and Gene Therapy Biological Testing Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Stem Cell and Gene Therapy Biological Testing Market Forecast

Buy Exclusive Report:

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

+1 775 237 4157

View post:
Stem Cell and Gene Therapy Biological Testing Market is thriving worldwide by 2029 | Top Key Players like Boehringer Ingelheim International GmbH.,...

University of So Paulo: In the future, cancer treatment should combine two types of immunotherapy, study suggests | India Education – India Education…

Cancer immunotherapy is currently one of the most effective approaches to treating patients. In it, cancer cells are fought by the bodys own immune system. Despite clinical success, not all people respond satisfactorily to this type of intervention or, if they do, they only have short-term responses, in addition to many side effects.

But a systematic review of the literature, carried out by Rafaela Rossetti, a doctoral student at the Clinical Oncology, Stem Cells and Cell Therapy Program at the Faculty of Medicine of Ribeiro Preto (FMRP) at USP, observed that the combination of two treatments (known as immunological checkpoint and adoptive transfer of genetically modified T cells) may bring promising results.

The article Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer was published in January 2022 in the journal Immunotherapy Advances .

These studies provide lessons on possible approaches to enhance the performance of immune system cells against cancer, making them more resistant to the immunosuppressive mechanisms [ which reduce the activity of this system ] imposed by the tumor microenvironment , explains Rafaela Rossetti to Jornal da USP .

T-CARs are T cells genetically modified in the laboratory to produce a type of protein known as CAR (which stands for Chimeric Antigen Receptor) before being cultured and returned to the sick person. There are six products approved by the Food and Drug Administration (FDA) the American drug regulatory agency for clinical use and available on the market.

The use of these cells has provided impressive results for the treatment of blood cancer. On the other hand, there are still limitations in its effectiveness against solid tumors, says Lucas Eduardo Botelho, coordinator of the Gene Transfer Laboratory at the Ribeiro Preto Blood Center and an associate researcher at the Cell Therapy Center (CTC), one of the Research, Innovation Centers and Diffusion (Cepids) funded by the So Paulo Research Foundation (Fapesp).

The inefficiency is due, in part, to the immunosuppression mechanisms employed by tumors to escape the attack mediated by immune system cells, says Botelho.

Blocking the immune checkpoint is based on a group of proteins present on the surface of T lymphocytes that need to be activated or inactivated to trigger an immune response. Previous studies, led by Americans and Japanese, have shown that cancer cells stimulate the expression of these proteins (called checkpoints ) and their ligands (triggers) in tumor tissue. As a result, tumors turn off the immune system, which favors cancer growth. The same scientists also demonstrated that the use of antibodies capable of inhibiting the interaction between checkpoints and their ligands restores the antitumor defense response, allowing the reactivation of T lymphocytes.

This review aimed to assess whether blocking immunological checkpoints would be a promising way to increase the therapeutic efficacy of genetically modified T cells against solid neoplasms, summarizes Botelho.

Preclinical and clinical trials Systematic review is a research method that seeks to bring together similar studies by critically evaluating them in their methodology and bringing them together in a statistical analysis. By synthesizing similar and good quality studies, it is considered the best level of evidence for decision-making on treatments, according to Cochrane , a global network of researchers specializing in systematic review works.

To carry out this review, Rafaela and Botelho defined the main points to be addressed and each of them contributed to the bibliographic search, contextualization and writing on the chosen topics. In this review, we sought to bring a compilation of studies that provided important insights, as well as pre-clinical and clinical studies published recently, explains Rafaela Rossetti .

The aim was to provide a more complete picture of the current scenario of using immune checkpoint inhibitors in combination with the infusion of genetically modified T cells for cancer treatment. In the end, 112 articles were selected for the researchers work.

In her opinion, this work contributed to enriching the knowledge in the area and allowed to reflect on possible implementations in research that currently address mainly genetically modified T cells for the treatment of cancer, aiming at an improvement in the efficiency of these cells.

Butantan, USP and Hemocentro de Ribeiro develop innovative cancer therapy The Cell Therapy Center was the pioneer in Brazil to establish an infrastructure for the study and clinical application of stem cells and, a few years ago, there was the incorporation of the use of genetically modified T cells to recognize and destroy tumor cells in the areas of research and development.

As a result, a platform was established for the production and clinical use of T cells expressing chimeric antigen receptors against the CD-19 protein (expressed in B-cell leukemias and lymphomas). This study resulted in the first successful application of anti-CD-19 T-CAR cells for the compassionate treatment of lymphoma patients in Latin America, says Botelho.

The Gene Transfer Laboratory of the Blood Center in Ribeiro Preto is making efforts to contribute to the expansion of the platform for the production and clinical use of CAR-T cells through the creation of molecular tools for quality control and pre-clinical tests, in addition to to develop new genetic constructs and strategies to improve the effectiveness and access of patients to this type of therapy.

Botelho says that, currently, there are projects underway to evaluate genetic constructs against three new targets expressed by tumor cells, including solid tumors. In addition, a gene editing platform for the generation of allogeneic T cells is under implementation.

This strategy can drastically reduce the costs of this technology, and allows cellular modifications capable of increasing its effectiveness through the deletion of genes that limit its antitumor activity, for example.

The survey we carried out reinforces the idea that using gene editing tools to delete the molecular circuits involved in this interaction can result in a more effective product, as it no longer suffers the suppressive action of the tumor microenvironment, emphasizes the last author of the study. Certainly this information will be incorporated into our effort to develop the next generation of anticancer cellular immunotherapies, he concludes.

Read the original here:
University of So Paulo: In the future, cancer treatment should combine two types of immunotherapy, study suggests | India Education - India Education...

Triplet Therapy Plus Transplantation Prolongs PFS in Multiple Myeloma – Targeted Oncology

Induction treatment with the triplet of lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (RVD) plus autologous stem cell transplantation (ASCT) was associated with longer progression-free survival (PFS) compared with RVD alone in patients with newly diagnosed multiple myeloma.

Findings showed that the median PFS was 46.2 months in the RVD-alone group and 67.5 months in the transplantation and RVD group. With a median follow-up of 76.0 months, 328 events of disease progression or death occurred with the risk 53% higher in the RVD-alone group than in the transplantation group (HR, 1.53; 95% CI, 1.23-1.91; P < .001).

Additionally, data published in the New England Journal of Medicine showed that the percentage of patients with a partial response (PR) or better was 95.0% in the RVD-alone group vs 97.5% in the transplantation group (P = .55). A total of 42.0% of patients in the RVD-alone group and 46.8% in the transplantation group had a complete response (CR) or better (P = .99).

The phase 3 DETERMINATION trial [NCT01208662] showed the superiority of ASCT-based first-line therapy with respect to progression-free survival among eligible patients with newly diagnosed myeloma, findings that confirm those of the IFM 2009 trial.We found a significant 21.3-month benefit in median progression-free survival and a 35% lower risk of disease progression or death with RVD plus ASCT than with RVD alone, wrote the study authors.

In this randomized, open-label phase 3 trial, adults aged 18 to 65 years of age with symptomatic myeloma received 1 cycle of RVD to examine it as the initial management strategy in this patient population.

Initially all patients received 1 cycle of RVD. Then, patients were randomly assigned in a 1:1 ratio to receive 2 additional RVD cycles plus stem cell mobilization. Randomization was stratified according to the International Staging System (ISS) disease stage and cytogenetic risk profile.

In both groups, patients received 2 additional cycles of RVD before stem cell collection. For those in the RVD-alone group, they received 5 additional RVD cycles vs those in the transplantation group who received high-dose melphalan at a dose of 200 mg/m2plus ASCT. At approximately day 60, patients in the transplantation group received 2 additional RVD cycles.

The 21-day cycle of RVD therapy included oral lenalidomide at 25 mg on days 1 through 14; intravenous or subcutaneous bortezomib at 1.3 mg/m2 on days 1, 4, 8, and 11; and oral dexamethasone at 20 mg in cycles 1 to 3 and 10 mg starting in cycle 4 on days 1, 2, 4, 5, 8, 9, 11, and 12. For both groups, maintenance therapy was made up of daily lenalidomide at 0 mg, with a possible increase to 15 mg thereafter until disease progression, unacceptable toxic effects, or withdrawal from treatment or the trial.

For patients in the RVD-alone group at relapse, off-trial salvage transplantation was recommended but not required after completion of the protocol-specified treatment. Patients in the transplantation group could undergo a second transplantation with the selection of subsequent therapies made by patient and physician decision.

Enrollment was open to patients with symptomatic, measurable, newly diagnosed myeloma, and an ECOG performance status of 0 to 2, myeloma measurable by serum or urine evaluation of the monoclonal component or by assay of serum-free light chains, and a negative HIV blood test. Patients who had previously used systemic therapy for myeloma, central nervous system involvement, primary amyloidosis, and inadequate hematologic, hepatic, renal, or cardiac function were ineligible to be enrolled.

The primary end point was PFS. Secondary end points included response rates, the duration of response (DOR), the time to disease progression, overall survival (OS), quality of life, and adverse events (AEs).

Out of the 873 recruited patients, 357 were randomly assigned to the RVD-alone group and 365 to the transplantation group. Baseline patient and disease characteristics were balanced between the 2 groups with the median age as 57 years (interquartile range, 25-66) in the RVD-alone group and 55 years (interquartile range, 30-65) in the transplantation group. There were 122 patients (34.2%) and 102 patients (27.9%) aged 60 years or older, the ISS disease stage was II or III in 179 patients in the RVD-alone group (50.1%) and in 181 patients in the transplantation group (49.6%), a high-risk cytogenetic profile was identified in 66 of 334 patients (19.8%) and 66 of 340 patients (19.4%), respectively, with data that could be evaluated by means of fluorescence in situ hybridization.

Findings showed that in the RVD-alone group, the median duration of treatment was 28.2 months (95% CI, 21.1-36.3) vs 36.1 months (95% CI, 28.5-41.5) in the transplantation group. Of the 365 patients in the transplantation group, 310 (84.9%) underwent ASCT. There were 289 patients (81.5%) in the RVD-alone group and 289 patients (79.2%) in the transplantation group who received lenalidomide maintenance therapy with the median duration being 36.4 months (95% CI, 25.7-40.8) and 41.5 months (95% CI, 34.0-47.1). At the time of data cutoff, 78 (26.8%) and 89 patients (30.8%) were still receiving maintenance therapy, respectively.

Additionally, the median percentage of maintenance cycles was 87.0% in the RVD-alone group and 60.0% in the transplantation group when the average lenalidomide dose was at least 10 mg. Then, 259 patients (89.0%) in the RVD-alone group and 264 patients (91.3%) in the transplantation group who received lenalidomide maintenance therapy had at least 1 dose modification, with 9854 dose modifications reported during maintenance therapy after RVD alone and 13,695 dose modifications after RVD plus ASCT. Dose modifications were due to AEs or illness in 50.5% of the RVD-alone group and 51.6% in the transplantation group.

Of the 328 patients with events of disease progression or death, there were 189 in the RVD-alone group (52.9%) and 139 in the transplantation group (38.1%). The duration of PFS among patients with a high-risk cytogenetic profile was 17.1 months in the RVD-alone group vs 55.5 months in the transplantation group. For disease progression, a secondary end point of the trial, the percentage of patients who were alive without progression at 5 years was 41.6% and 58.4%, respectively (HR, 1.66; 95% CI, 1.21-2.27).

Additionally, the median DOR was 38.9 months in the RVD-alone group vs 56.4 months in the transplantation group (HR, 1.45; 95% CI, 1.09-1.93), and the percentage of patients with a CR or better at 5 years was 52.9% and 60.6%, respectively.

In regard to safety, hematologic treatment-related AEs (TRAEs) that occurred were neutropenia (42.6% with RVD alone vs 86.3% with transplantation), thrombocytopenia (19.9% vs 82.7%, respectively), leukopenia (19.6% vs 39.7%), anemia (18.2% vs 29.6%), lymphopenia (9.0% vs 10.1%), and febrile neutropenia (4.2% vs 9.0%). Other TRAEs included diarrhea (3.9% in the RVD-alone group vs 4.9% in the transplantation group), nausea (0.6% vs 6.6%, respectively), fatigue (2.8% vs 6.0%), fever (2.0% vs 5.2%), pneumonia (5.0% vs 9.0%), hypophosphatemia (9.5% vs 8.2%), hyperglycemia (2.5% vs 4.1%), hypokalemia (3.4% vs 1.9%), neuropathy (5.6% vs 7.1%) syncope (2.2% vs 1.9%), and maculopapular rash (2.8% vs 3.6%).

Overall, grade 3 of higher TRAE occurred in 279 patients (78.2%) in the RVD-alone group and 344 patients (94.2%) in the transplantation group. Serious RVD-related AEs were observed in 144 patients in the RVD-alone group (40.3%) and 172 patients in the transplantation group (47.1%). Further, treatment-related serious infections were reported during maintenance therapy in 33 patients (11.3%) and 48 (16.6%), respectively.

Our results also highlight the value of long-term lenalidomide maintenance therapy until disease progression in both groups. In our trial, the median progression-free survival among patients who received RVD alone was 11.2 months longer than that in the IFM 2009 trial [46.2 vs. 35.0 months]; in the latter trial, patients received the same treatment as in the current trial except with only 1 year of maintenance therapy, wrote the study authors. The median progression-free survival among patients who received RVD plus ASCT was 20.2 months longer in our trial than in the IFM 2009 trial [67.5 vs 47.3 months]. These findings confirm previous observations of increased progression-free survival with a greater duration of lenalidomide maintenance therapy.

Read the original:
Triplet Therapy Plus Transplantation Prolongs PFS in Multiple Myeloma - Targeted Oncology

Higher doses of CAR-T therapy bring survival advantage for young patients with hard-to-treat B-ALL – EurekAlert

First dosing study using real-world data offers valuable insights to inform treatment decisions

(WASHINGTON, August 8, 2022) Young people who received doses of tisagenlecleucel, a chimeric antigen receptor T cell (CAR-T) therapy, at the higher end of the FDA-approved dosing range had significantly better survival rates at one year compared with those who received lower doses within this range, according to research published today in Blood Advances.

Since its approval as the first gene therapy available in the United States in 2017, tisagenlecleucel has offered a welcome treatment option for pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL) whose cancer does not respond to chemotherapy or recurs after prior response. However, the wide dosing range approved for the therapy can pose a conundrum for doctors who sometimes must choose whether to use a higher or lower dose with little evidence to guide these decisions. This new study offers the first insights into optimal dosing based on real-world data.

In the past, we did not have data to guide clinical decisions around commercial CAR T-cell dosing and didnt know if higher doses would affect toxicity and compromise outcomes, or support enhanced anti-leukemia effect, said Liora Schultz, MD, pediatric oncologist at the Stanford Children's Health | Lucile Packard Children's Hospital, and the studys lead author. This data has direct clinical applicability, as it supports use of higher dosing, as available, within the approved tisagenlecleucel dose range.

ALL is the most common type of cancer in children, and B-ALL is its most common subtype. It is often treatable with chemotherapy, but about 20% of patients one out of five either do not respond to chemotherapy or subsequently relapse. CAR T-cell therapy is a type of immunotherapy in which a patients T cells, immune cells in the body that fight infection, are removed, genetically modified in a laboratory to help them identify cancer cells, and then infused back into the patients bloodstream where they find and destroy cancer cells. This therapy is becoming an integral part of standard care as an alternative or supplement to stem cell transplantation for pediatric patients with relapsed or refractory B-ALL.

Tisagenlecleucel is approved at a dosing range of 0.2 to 5 million CAR T cells/kg for patients weighing 50 kilograms or less, or 10 to 250 million CAR T cells for patients over 50 kilograms. In practice, the number of CAR T cells that are manufactured for each patient varies substantially based on the number of T cells that are obtained initially and the rate at which the modified cells grow in the laboratory.

Any amount of CAR T cells within the approved range is considered an acceptable dose, but if more than the minimum number of cells are available within the approved range, doctors can decide whether to use a higher amount or a lower amount. Clinical trials for tisagenlecleucel provided guidance on dosing leading to the therapys approval, but real-world data is useful to fine-tune dosing and inform decision making when there are multiple options available.

For the study, researchers analyzed rates of overall survival, event-free survival, and relapse-free survival at one year among 185 patients aged 26 or younger who received tisagenlecleucel for relapsed or refractory B-ALL. They found that patients who received a dose at the higher end of the approved range (between 2.4 and 5.1 million cells/kg) had significantly higher survival rates according to all three measures compared with patients who received a dose at the lower end (between zero and 1.3 million cells/kg). In the highest dose group, 86% of patients were alive at one year, compared to 59% in the lowest dose group. Researchers did not observe any signs of increased toxicity or safety concerns with higher doses.

The findings suggest that administering doses of tisagenlecleucel at the higher end of the approved range could help to achieve a more effective and long-term response without raising the toxicity risk. A lot of effort is focused on complex engineering and development of next-generation CAR-T therapies, said Dr. Schultz. This study aims to explore if clinical manipulations using our current approved construct, tisagenlecleucel, can achieve even incremental advances in the field.

The researchers plan to further examine the data to determine how additional clinical variables, might influence outcomes following CAR T cell therapy.

# # #

Blood Advances is a peer-reviewed, online only, open access journal of the American Society of Hematology (ASH), the worlds largest professional society concerned with the causes and treatment of blood disorders.

Blood Advances is a registered trademark of the American Society of Hematology.

Contact:

Kira Sampson, American Society of Hematology

ksampson@hematology.org; 202-499-1796

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

See original here:
Higher doses of CAR-T therapy bring survival advantage for young patients with hard-to-treat B-ALL - EurekAlert

See-through zebrafish, new imaging method put blood stem cells in high-resolution spotlight – University of Wisconsin-Madison

Tracing features in a large 3D electron microscopy dataset reveals a zebrafish blood stem cell (in green) and its surrounding niche support cells, a group photo method that will help researchers understand factors that contribute to blood stem cell health which could in turn help develop therapies for blood diseases and cancers. Image by Keunyoung Kim.

MADISON For the first time, researchers can get a high-resolution view of single blood stem cells thanks to a little help from microscopy and zebrafish.

Researchers at the University of WisconsinMadison and the University of California San Diego have developed a method for scientists to track a single blood stem cell in a live organism and then describe the ultrastructure, or architecture, of that same cell using electron microscopy. This new technique will aid researchers as they develop therapies for blood diseases and cancers.

Currently, we look at stem cells in tissues with a limited number of markers and at low resolution, but we are missing so much information, says Owen Tamplin, an assistant professor in UWMadisons Department of Cell & Regenerative Biology, a member of the Stem Cell & Regenerative Medicine Center, and a co-author on the new study, which was published Aug. 9 in eLife. Using our new techniques, we can now see not only the stem cell, but also all the surrounding niche cells that are in contact.

The niche is a microenvironment found within tissues like the bone marrow that contain the blood stem cells that support the blood system. The niche is where specialized interactions between blood stem cells and their neighboring cells occur every second, but these interactions are hard to track and not clearly understood.

As a part of the new study, Tamplin and his co-lead author, Mark Ellisman, a professor of neuroscience at UC San Diego, identified a way to integrate multiple types of microscopic imaging to investigate a cells niche. With the newly developed technique that uses confocal microscopy, X-ray microscopy, and serial block-face scanningelectron microscopy, researchers will now be able to track the once elusive cell-cell interactions occurring in this space.

This has allowed us to identify cell types in the microenvironment that we didnt even know interacted with stem cells, which is opening new research directions, Tamplin says.

As a part of this study, Tamplin, and his colleagues, including co-first authors Sobhika Agarwala and Keunyoung Kim, identified dopamine beta-hydroxylase positive ganglia cells, which were previously an uncharacterized cell type in the blood stem cell niche. This is crucial, as understanding the role of neurotransmitters like dopamine in regulating blood stem cells could lead to improved therapeutics.

Transplanted blood stem cells are used as a curative therapy for many blood diseases and cancers, but blood stem cells are very rare and difficult to locate in a living organism, Tamplin says. That makes it very challenging to characterize them and understand how they interact and connect with neighboring cells.

While blood stem cells are difficult to locate in most living organisms, the zebrafish larva, which is transparent, offers researchers a unique opportunity to view the inner workings of the blood stem cell niche more easily.

Thats the really nice thing about the zebrafish and being able to image the cells, Tamplin says of animals transparent quality. In mammals, blood stem cells develop in utero in the bone marrow, which makes it basically impossible to see those events happening in real time. But, with zebrafish you can actually watch the stem cell arrive through circulation, find the niche, attach to it, and then go in and lodge there.

While the zebrafish larva makes it easier to see blood stem cell development, specialized imaging is needed to find such small cells and then detail their ultrastructure. Tamplin and his colleagues spent over six years perfecting these imaging techniques. This allowed them to see and track the real-time development of a blood stem cell in the microenvironment of a live organism, then zoom in even further on the same cell using electron microscopy.

First, we identified single fluorescently labeledstem cells bylight sheet or confocal microscopy, Tamplin says. Next, we processed the same sample forserial block-face scanningelectron microscopy. We then aligned the 3D light and electron microscopy datasets. Byintersecting these different imaging techniques,we could see the ultrastructure of single rare cells deep inside a tissue. This also allowed us to find all the surrounding niche cellsthat contact a blood stem cell. We believe our approach will be broadly applicable for correlative light and electron microscopy in many systems.

Tamplin hopes that this approach can be used for many other types of stem cells, such as those in the gut, lung, and the tumor microenvironment, where rare cells need to be characterized at nanometer resolution. But, as a developmental biologist, Tamplin is especially excited to see how this work can improve researchers understanding of how the blood stem cell microenvironment forms.

I think this is really exciting because we generate all of our blood stem cells during embryonic development, and depending on what organism you are, a few hundred or maybe a few thousand of these stem cells will end up producing hundreds of billions of new blood cells every day throughout your life, Tamplin says. But we really dont know much about how stem cells first find their home in the niche where theyre going to be for the rest of the life of the organism. This research will really help us to understand how stem cells behave and function. A better understanding of stem cell behavior, and regulation by surrounding niche cells, could lead to improved stem cell-based therapies.

This research was supported by grants from the National Institutes of Health (R01HL142998, K01DK103908, 1U24NS120055-01, R24 GM137200) and the American Heart Association (19POST34380221).

The rest is here:
See-through zebrafish, new imaging method put blood stem cells in high-resolution spotlight - University of Wisconsin-Madison

First-Ever Embryos With Monkey And Human Cells; Scientists Divided Over The Creation – Boldsky

Wellness

oi-Amritha K

For the first time, scientists have successfully grown monkey embryos containing human cells, marking a milestone in a rapidly advancing field that has raised ethical concerns.

Human stem cells may one day be used to grow new organs for people with failing hearts or kidneys by slipping them into the embryos of other animals. To achieve this goal, researchers have created the first embryos that contain human and monkey cells.

Researchers may be able to refine techniques for growing human tissue in species better suited for transplantation, such as pigs, by studying these chimaeras [1].

In genetics, a chimaera is an organism or tissue that contains at least two sets of DNA, most commonly resulting from the fusion of several zygotes (fertilized eggs). In Greek mythology, the term Chimera refers to a fire-breathing monster that was part lion, part goat, and part dragon [2].

According to the study published in the journal Cell, researchers in the United States and China injected 25 pluripotent stem cells (pluripotent stem cells of the body are capable of self-renewal and give rise to all cells of the body's tissues) from humans into monkey embryos.

After one day, researchers detected the development of human cells in 132 embryos, and the embryos ultimately survived for 19 days.

"The paper is a landmark in the stem cell and interspecies chimaera fields. The findings hint at mechanisms by which cells of one species can adjust to survive in the embryo of another", added experts [3].

According to the researchers, a third of the chimaeras had human cells present after 13 days. There appears to be an integration of human cells with monkey cells, and the human cells have begun to specialize into different types of cells that will develop into different organ types. A few previous studies by researchers in the same study group had explored embryo development along the same lines:

Researchers identified molecular pathways that were turned on or up in the chimaeras, possibly promoting the integration of human and monkey cells. Researchers believe that manipulating some of these pathways may allow human cells to survive in embryos of species more suitable for regenerative medicine for health problems.

However, the findings also stated that the human and monkey cells did not mesh perfectly. Human cells often stuck together, leading researchers to wonder if there is another barrier they are unaware of that would prevent human cells from thriving if the embryos mature further.

Chimaeras consisting of humans and monkeys do raise some concerns.

Last week, the National Academies of Sciences, Engineering, and Medicine released a report suggesting that human nerve cells may enter the brains of animals and alter their mental capabilities [7].

In this study, however, there are no nervous systems in the chimaeras. Therefore, it is impossible for them to experience pain and not be conscious. However, experts believe the story would be very different if human-monkey chimaeras were permitted to develop further - suggesting that it could go out of their hands.

"My first question is: Why?" Kirstin Matthews, a science and technology fellow at Rice University's Baker Institute, said, "I think the public is going to be concerned, and I am as well, that we're just kind of pushing forward with science without having a proper conversation about what we should or should not do" [8].

According to the researchers, they do not intend to implant any hybrid embryos into monkeys. Instead, the goal is to better understand how different cells communicate with one another during the early stages of embryonic development.

Several scientists question the need for such experiments using closely related primates - these animals are unlikely to be used as model animals in the same way as mice and rodents. Researchers are concerned that such work may stoke public opposition as non-human primates are protected by stricter research ethics rules than rodents [9][10].

Although there are concerns, scientists hope that these human-animal hybrids, known as chimaeras, can provide better models for testing drugs and growing human organs for transplantation.

prenatal

What To Know About Superfetation (Getting Pregnant While Pregnant)

basics

Can A Blighted Ovum Cause A Positive Pregnancy Test?

insync

Viagra Boosts Conception!

prenatal

Steroid Treatment May Prevent Miscarriages

prenatal

Coffee Cuts Pregnancy Chances In Women

prenatal

Here's what causes morning sickness

prenatal

DNA Fingerprinting Breakthrough

health

Bangalore Hospital Performs Karnataka's Youngest Heart Transplant

news

Indian Student Develops AI Organ Donation App, Wins Microsoft's AI For Good Idea Challenge 2019

wellness

Skin Grafting: Types, Procedure And Complications

wellness

Nutrition After Blood And Marrow Transplant

wellness

Kidney Transplant: Do's And Dont's During Surgery & Post Surgery

GET THE BEST BOLDSKY STORIES!

Allow Notifications

You have already subscribed

Story first published: Tuesday, August 9, 2022, 16:35 [IST]

Original post:
First-Ever Embryos With Monkey And Human Cells; Scientists Divided Over The Creation - Boldsky